Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Jolkinolide B (CAS No.: 37905-08-1) is a diterpene natural product derived from Euphorbia fischeriana. As a natural compound with significant bioactivity, Eugenolide B has attracted widespread attention in recent years due to its excellent antitumor activity. Multiple studies have shown that this compound can induce cancer cell apoptosis through various molecular mechanisms, inhibit tumor cell proliferation and migration, and demonstrates promising pharmacological potential. This paper systematically reviews the chemical structure and physicochemical properties of Euphorbide B, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, pharmacokinetic characteristics, and clinical application prospects, aiming to provide theoretical basis and reference for in-depth research and drug development of this natural product.

Chemical structure and physicochemical properties

Euspurge Eucidide B belongs to the diterpene lactone compound, with a molecular formula of C20H26O5 and a molecular weight of 330.4240. Its structural feature is a typical diterpene skeleton, containing an lactone ring and multiple oxygen functional groups, giving it unique biological activity. According to calculations, its LogP value is 4.1364, indicating good lipid solubility, which is beneficial for cell membrane penetration. The polar surface area (TPSA) was 51.3600, indicating moderate molecular polarity, which may affect its bioavailability and targeting. Its low water solubility (0.0084 mg/mL) somewhat limits its drug formulation development, but its high lipophilic solubility facilitates oral absorption and blood-brain barrier penetration. Related studies show it has a strong blood-brain barrier penetration capability. Additionally, Eupherus b, the Euphorbide B, did not show hERG channel inhibition, suggesting a low risk of cardiotoxicity; The Ames test result was 0.9, indicating a low genotoxicity risk and a solid safety foundation.

Plant Origins and Extraction Methods

Euphorbia fischeriana steud. Wolf Euphorbia belongs to the Euphorbiaceae family, widely distributed in Northeast China and the Korean Peninsula. It has long been used as a traditional Chinese medicine to treat tumors, inflammation, and infectious diseases. Traditional methods for extracting Euspurge Eudonolide B include ethanol or methanol leaching, followed by liquid-liquid partitioning, column chromatography (such as silica gel columns, reversed-phase C18 columns), and high-performance liquid chromatography (HPLC) purification to obtain high-purity target compounds. In recent years, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has improved extraction efficiency and purity, reducing solvent usage and extraction time. In addition, regarding the structural characteristics of Euspurge Euphorbide B, researchers have developed selective adsorbent materials based on molecular blotching technology for efficient separation and purification.

Pharmacological activity research

Antitumor activity

The antitumor effect of Euphorbide B is its most notable biological activity, covering various cancer types including but not limited to breast cancer, lung cancer, liver cancer, colorectal cancer, and leukemia. In vitro cell experiments showed that Euphriolide B significantly inhibits tumor cell proliferation, inducing cell cycle arrest and apoptosis. Its IC50 value is usually at the micromolar level, indicating strong cytotoxicity. Animal model studies further confirmed its antitumor effect. Euphridonolide B can effectively inhibit tumor growth, prolong survival in experimental animals, and have minimal toxic side effects.

Induces apoptosis of cancer cells

Euspurge olide B induces programmed death of cancer cells by activating endogenous and exogenous apoptosis pathways. Its mechanism involves loss of mitochondrial membrane potential, activation of the caspase family (such as caspase-3, caspase-9), and regulation of the expression of BCL-2 family proteins. In addition, Euphriolide B can promote intracellular ROS (reactive oxygen species) production, induce oxidative stress, and further enhance the transmission of apoptosis signals.

Anti-metastasis and anti-angiogenesis

Euphriolide B inhibits the migration and invasion of tumor cells. It inhibits matrix degradation and infiltration by downregulating the expression of matrix metalloproteinase MMP2. At the same time, Euphriolide B can inhibit tumor-associated angiogenesis, with part of its mechanism regulating the HIF1A (hypoxia-inducing factor 1α) signaling pathway, blocking angiogenesis in the tumor microenvironment and limiting tumor nutrient supply.

Mechanism of action and molecular targets

The antitumor effects of Euphrigo Euphorbide B involve multiple key molecular targets and signaling pathways, reflecting its pharmacological characteristics of multiple targets and mechanisms.

• MCL1 and BCL2: Euspur olide B disrupts the intracellular apoptosis inhibitory network by downregulating the expression of anti-apoptotic proteins MCL1 and BCL2, thereby promoting mitochondrial pathway apoptosis.
• STAT3: As an important transcription factor for tumor cell proliferation and immune evasion, STAT3's activity is inhibited by Euphridonolide B, blocking the expression of downstream growth promotion and anti-apoptotic genes.
• MMP2: By inhibiting MMP2 expression, Euspsurge lactone B reduces the stromal degradation capacity of tumor cells and suppresses tumor metastasis.
• TOP1 and TOP2A: As DNA topoisomerases, TOP1 and TOP2A play key roles in DNA replication and transcription. Euspurge lactone B inhibits these two enzymes, leading to DNA damage and cell cycle arrest.
• HIF1A: Euphriolide B inhibits the stability and activity of HIF1A, suppresses tumor hypoxia adaptation mechanisms, and blocks tumor angiogenesis.
• MAPK1: Euspurge lactone B regulates the MAPK signaling pathway, affecting cell proliferation, differentiation, and apoptosis.
• ESR1 and CYP19A1: In hormone-dependent tumors, Eusphorbide B intervenes hormone signaling and inhibits tumor growth by regulating the expression of estrogen receptors (ESR1) and aromatase (CYP19A1).

This multi-target mechanism enables Euphurge lactone B to demonstrate broad adaptability and potential synergistic effects in anti-tumor therapy.

Druggability evaluation and pharmacokinetics

The druggability evaluation of Euspsurge lactone B shows it has certain advantages and challenges. Its high lipid solubility (LogP=4.1364) facilitates cell membrane penetration and oral absorption, but its lower water solubility (0.0084 mg/mL) limits its bioavailability and formulation development. Its moderate polar surface area (TPSA=51.3600) facilitates penetration of the blood-brain barrier, and related experiments support its potential application in central nervous system diseases.

In terms of safety, Eusphurium litholactone B did not show significant hERG channel inhibition, reducing the risk of cardiotoxicity. The Ames test result was 0.9, indicating low genotoxicity and good safety. Pharmacokinetic studies have shown that Euspurge Eucidide B has good distribution characteristics in the body and can effectively enter tumor tissues. Its metabolic pathway mainly involves liver enzyme systems, and the metabolites still require further identification and evaluation.

Currently, the oral bioavailability and in vivo half-life of Euspurge petrolactone B still need optimization, and the development of novel delivery systems such as nanocarriers and liposomes offers potential for clinical translation.

Prospects and outlooks for clinical applications

Euspsurge B, a natural compound with multi-target antitumor activity, has promising clinical application potential. Its multiple mechanisms of inducing cancer cell apoptosis, inhibiting tumor metastasis, and inhibiting angiogenesis provide new ideas for comprehensive tumor treatment. Especially in drug-resistant tumors and multidrug combination therapy, Euphthalis B is expected to play a synergistic effect.

Future research should focus on the following areas:

1. In-depth mechanism analysis: Using multi-omics techniques such as genomics and proteomics, the molecular network of Eupolidon b's action and its interactions with the tumor microenvironment were further clarified.
2. Pharmacokinetic optimization: Through structural modification and advanced delivery systems, it improves water solubility, bioavailability, and targeting, reducing potential toxic side effects.
3. Preclinical safety evaluation: Systematically evaluate its toxicological characteristics to ensure safety for clinical application.
4. Clinical trial design: Conduct early clinical trials to verify efficacy and safety, and explore combination drug strategies.
5. Indication expansion: Beyond tumors, explore its potential applications in inflammation, autoimmune, and neurodegenerative diseases.

In summary, Euphthium Euphorbide B, as a multifunctional natural product, has the potential to become a novel antitumor drug and deserves further in-depth research and development.

Conclusion

Euspurge lide B, an important diterpenoid active ingredient in Euspurge lantoxin, has become a hot topic in natural product pharmacology research due to its unique chemical structure and significant antitumor activity. It regulates tumor cell growth, apoptosis, and metastasis through multiple targets and pathways, demonstrating good pharmacological efficacy and a foundation of safety. Although its water solubility and pharmacokinetic characteristics have certain limitations, with the help of modern drug design and formulation technology, clinical translation is expected to be achieved. In the future, as mechanistic research deepens and clinical evaluations advance, Euphridonolide B is expected to become an important drug in the field of anti-tumor therapy, offering new treatment options for cancer patients.